Skip to main
  1. Stocks
  2. Novavax
  3. Forecast
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 20%

Bulls say

Novavax is supported by a broadened revenue base and clearer partner economics, as 3Q delivered $68M of topline, $6.1M of Sanofi royalties, and $42.6M of licensing revenue while FY26 revenue guidance was raised to $385M-$415M. The Sanofi collaboration de-risks the story by triggering a $125M milestone in 4Q and confirming a US Ph3 start in 2027, which could unlock another $225M on first commercial sale, even as non-GAAP breakeven shifts to early 2029. Beyond COVID, its Matrix-M platform and wholly owned pipeline add optionality, with a lead C. diff candidate targeting clinic entry as early as 2027 and cash of $627M, or $676M with receivables, funding operations into 2029.

Bears say

Novavax is facing a weakened 2027 revenue bridge as APA product sales drop out, R&D reimbursement falls to about $5M, and Sanofi upfront amortization declines to under $5M, leaving heavier reliance on royalties, supply, and a $75M technology transfer milestone expected in 3Q27. The company’s outlook is also exposed to execution risk because Sanofi controls SP0287 Phase 3 timing, delayed milestones could push it toward dilutive financing despite more than $700M of cash and securities, and in-the-money converts add about 22M shares. Competitive pressure from Pfizer/BioNTech and Moderna, possible regulatory demands beyond the assumed immunogenicity path, and patent challenges on Matrix-M further weaken the durability of its revenue base and partnership value.

Novavax (NVAX) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Novavax (NVAX) Analyst Forecast & Price Prediction

Get the latest Novavax (NVAX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Novavax (NVAX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Buy based on their latest research and market trends.

According to 5 analysts, Novavax (NVAX) has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Novavax (NVAX) Analyst Forecast & Price Prediction

Get the latest Novavax (NVAX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Novavax (NVAX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NVAX stock data and trends